



Barts and The London

School of Medicine and Dentistry

INSTITUTE OF CELL AND MOLECULAR SCIENCE: HIV RESEARCH DAY - A SYMPOSIUM 3RD JULY 2008				
Time	Session Title	Chair	Speaker	Talk title
8.30AM	REGISTRATION OUTSIDE PERRIN LECTURE THEATRE - BLIZARD BUILDING (INSTITUTE OF CELL AND MOLECULAR SCIENCE)			
9.15	Introduction	Aine McKnight & Tom McDonald		
9.30	Epidemiology	Chloe Orkin	Jane Anderson	HIV in east London - A view from the Clinic
9.45			Deenan Pillay	Biology and molecular epidemiology of HIV drug resistance
10.00			Katherine Groves	HIV-1 proviral loads in elite suppressors with low or declining CD4+ counts
10.15	Vaccines (1)	Robin Weiss	Jonathan Heeney	HIV vaccine strategies that induce both CTL and neutralising antibodies
10.30			Quentin Sattentau	New adjuvants to induce HIV-1 neutralising antibodies
10.45			Jonathan Weber	HIV vaccine trials in the UK; recent phase I results and plans for the future
11.00	TEA/COFFEE BREAK IN MARQUEE			
11.30	Vaccines (2)	Ian Jones	Neil Almond	Animal challenge models: What are they good for?
11.45			Steve Patterson	Possible mechanism of increased susceptibility to HIV infection after adenovirus vector vaccination
12.00PM			Philip Goulder	HIV adaptation to HLA
12.15			Martin Cranage	Rectal prophylaxis with tenofovir protects macaques and facilitates the priming of SIV-specific T cells
12.30	LUNCH IN MARQUEE			
1.30	Antivirals	Frances Gotch	Brian Gazzard	A different way of looking at studies
2.00			Kelly Cheney	IFN restriction of HIV replication
2.15			Matthias Dittmar	Old and new antiretrovirals: should fitness costs be considered?
2.30			Anna Maria Geretti	Exploring the determinants of antiretroviral treatment failure
2.45	TEA/COFFEE BREAK IN MARQUEE			
3.15	Life Cycle	Andrew Lever	Ian Harrison	Actin on Lv2
3.30			Ari Fassati	Nuclear transport of HIV
3.45			Stuart Neil	Antiviral restriction of HIV particle release
4.00			Juan Martin-Serrano	No strings attached: The ESCRT machinery in HIV-1 budding and cytokinesis
4.15			Mark Marsh	HIV assembly in macrophages - a special scenario
4.30		Áine McKnight	Robert Gallo	HIV/AIDS research: A few lessons from the early years and some perspectives on targeting CCR5 (therapy) and preventing env interaction with CCR5 (vaccine)
5.30	FINISH			
5.30	RECEPTION IN MARQUEE			